Cancer

Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting ≥1…

1 year ago

Cosmos Health to Participate at Capital Link’s ‘Invest in Greece’ Forum in New York

CHICAGO, IL / ACCESSWIRE / December 8, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

1 year ago

PRECEDE Consortium Marks Milestone in Pancreatic Cancer Battle with 5th Annual Meeting

Global experts gather at Cornell Tech, advancing early detection and survival in pancreatic cancer fightNEW YORK, NY / ACCESSWIRE /…

1 year ago

Quest International and CLS America Forge Partnership to Accelerate Commercialization Efforts for the TRANBERG Laser Ablation System in US Market

IRVINE, CA / ACCESSWIRE / December 8, 2023 / Quest International, a global aftermarket service support partner for Healthcare and…

1 year ago

Milestone Scientific Commences Sales of CompuFlo®  Disposables for Use in Neurostimulation Spinal Cord Implantation Procedures

Adoption of the technology at UTMB Health Clear Lake Campus Hospital follows successful evaluation process in these procedures—reporting 100% success…

1 year ago

AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in…

1 year ago

Cosmos Health Enters into Agreement to Acquire Rights for WIPO-Filed Patent on Drug Targeting CNS Cancers

CHICAGO, IL / ACCESSWIRE / December 7, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

1 year ago

AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism

122 Patients Enrolled in Single-arm IDE Study; 30-Day Follow-upLATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology…

1 year ago

AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism

122 Patients Enrolled in Single-arm IDE Study; 30-Day Follow-upLATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology…

1 year ago